Read news on lilly with our app.
Read more in the app
Lilly's oral GLP-1, orforglipron, is successful in third Phase 3 trial, triggering global regulatory submissions this year for the treatment of obesity
Marcos Vilela wins Lilly Research Award for Doctoral Students - EurekAlert